Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy
2018 ASH Annual Meeting & ExpositionJulie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from a multicenter study of axicabtagene ciloleucel CD19 CAR T-cell therapy for relapsed or refractory aggressive B-cell lymphoma when used as a standard of care (Abstract 91).
Related Videos
Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group
Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunothe...
John P. Leonard, MD, on NHL: Results From the AUGMENT Trial
John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Treatment Trial Results
Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagn...
Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study
Jennifer Ann Woyach, MD, of The Ohio State University, discusses trial findings on ibrutinib alone or in combination with rituximab compared with bendamustine plus rituximab in unt...
Mikkael A. Sekeres, MD, on MDS: Results From the Medalist Trial
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses phase III study findings on luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysp...
